Vivos Therapeutics Inc Financials

VVOS

Source SEC Filings (10-K/10-Q) Updated Sep 30, 2025 Currency USD FYE December

This page shows Vivos Therapeutics Inc (VVOS) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 39/100

Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Vivos Therapeutics Inc has an operating margin of -74.3%, meaning the company retains $-74 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -125.3% the prior year.

Growth

Vivos Therapeutics Inc's revenue grew 8.9% year-over-year to $15.0M, a solid pace of expansion. This earns a growth score of 54/100.

Leverage

100

Vivos Therapeutics Inc carries a low D/E ratio of 0.15, meaning only $0.15 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

Vivos Therapeutics Inc's current ratio of 1.50 indicates adequate short-term liquidity, earning a score of 40/100. The company can meet its near-term obligations, though with limited headroom.

Cash Flow

While Vivos Therapeutics Inc generated -$12.7M in operating cash flow, capex of $568K consumed most of it, leaving -$13.3M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.

Piotroski F-Score Neutral

4/9

Vivos Therapeutics Inc passes 4 of 9 financial strength tests. 1 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality Low Quality

1.14x

For every $1 of reported earnings, Vivos Therapeutics Inc generates $1.14 in operating cash flow (-$12.7M OCF vs -$11.1M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Revenue

$15.0M

YoY+8.9%

5Y CAGR+5.7%

Vivos Therapeutics Inc generated $15.0M in revenue in fiscal year 2024. This represents an increase of 8.9% from the prior year.

EBITDA

-$10.6M

YoY+36.5%

Vivos Therapeutics Inc's EBITDA was -$10.6M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 36.5% from the prior year.

Free Cash Flow

-$13.3M

YoY-4.0%

Vivos Therapeutics Inc generated -$13.3M in free cash flow in fiscal year 2024, representing cash available after capex. This represents a decrease of 4.0% from the prior year.

Net Income

-$11.1M

YoY+18.0%

Vivos Therapeutics Inc reported -$11.1M in net income in fiscal year 2024. This represents an increase of 18.0% from the prior year.

EPS (Diluted)

$-2.22

Vivos Therapeutics Inc earned $-2.22 per diluted share (EPS) in fiscal year 2024. This represents an increase of 80.1% from the prior year.

Cash & Debt

$6.3M

YoY+281.0%

5Y CAGR+67.9%

Vivos Therapeutics Inc held $6.3M in cash against $1.2M in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

Vivos Therapeutics Inc had 6M shares outstanding in fiscal year 2024. This represents an increase of 221.2% from the prior year.

Gross Margin

60.0%

YoY+0.1pp

5Y CAGR-16.0pp

Vivos Therapeutics Inc's gross margin was 60.0% in fiscal year 2024, indicating the percentage of revenue retained after direct costs. This is up 0.1 percentage points from the prior year.

Operating Margin

-74.3%

YoY+51.0pp

5Y CAGR+18.5pp

Vivos Therapeutics Inc's operating margin was -74.3% in fiscal year 2024, reflecting core business profitability. This is up 51.0 percentage points from the prior year.

Net Margin

-74.1%

YoY+24.3pp

5Y CAGR+20.3pp

Vivos Therapeutics Inc's net profit margin was -74.1% in fiscal year 2024, showing the share of revenue converted to profit. This is up 24.3 percentage points from the prior year.

Return on Equity

N/A

R&D Spending

$100K

YoY+0.0%

Vivos Therapeutics Inc invested $100K in research and development in fiscal year 2024. This represents an increase of 0.0% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$568K

YoY-29.3%

5Y CAGR+26.5%

Vivos Therapeutics Inc invested $568K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 29.3% from the prior year.

VVOS Income Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Revenue	$15.0M+8.9%	$13.8M-13.9%	$16.0M-5.1%	$16.9M+29.2%	$13.1M+14.7%	$11.4M
Cost of Revenue	$6.0M+2906.0%	$200K0.0%	$200K-50.0%	$400K+300.0%	$100K-96.3%	$2.7M
Gross Profit	$9.0M+9.0%	$8.3M-17.4%	$10.0M-20.5%	$12.6M+21.0%	$10.4M+20.3%	$8.7M
R&D Expenses	$100K0.0%	$100K-50.0%	$200K0.0%	$200K	N/A	N/A
SG&A Expenses	$17.9M-20.5%	$22.5M-22.6%	$29.0M+12.6%	$25.8M+60.3%	$16.1M-0.5%	$16.2M
Operating Income	-$11.2M+35.4%	-$17.3M+30.9%	-$25.0M-22.8%	-$20.4M-69.3%	-$12.0M-13.8%	-$10.6M
Interest Expense	N/A	N/A	N/A	$14K-85.4%	$96K-30.4%	$138K
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$11.1M+18.0%	-$13.6M+43.0%	-$23.8M-17.5%	-$20.3M-68.3%	-$12.1M-12.1%	-$10.8M
EPS (Diluted)	$-2.22	$-11.14	$-25.90	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q3'24	Q2'24	Q1'24	Q4'23
Revenue	$6.8M+77.6%	$3.8M+26.7%	$3.0M-18.4%	$3.7M-4.2%	$3.9M-4.8%	$4.1M+18.6%	$3.4M+5.3%	$3.2M
Cost of Revenue	$2.8M+66.4%	$1.7M+13.5%	$1.5M-49.5%	$3.0M+95.5%	$1.5M+8.8%	$1.4M+1303.0%	$100K+200.0%	-$100K
Gross Profit	$3.9M+86.6%	$2.1M+39.8%	$1.5M-28.0%	$2.1M-10.2%	$2.3M-12.0%	$2.7M+36.9%	$1.9M-7.3%	$2.1M
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	$100K+150.0%	-$200K
SG&A Expenses	$7.9M+23.0%	$6.4M+31.0%	$4.9M+12.5%	$4.3M-3.1%	$4.5M+8.9%	$4.1M-16.2%	$4.9M-10.0%	$5.5M
Operating Income	-$4.7M+2.7%	-$4.9M-24.2%	-$3.9M-39.7%	-$2.8M-6.0%	-$2.6M-36.6%	-$1.9M+48.9%	-$3.8M+8.4%	-$4.1M
Interest Expense	$500K	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$5.4M-7.7%	-$5.0M-29.7%	-$3.9M-36.7%	-$2.8M-8.1%	-$2.6M-35.5%	-$1.9M+48.7%	-$3.8M+11.6%	-$4.3M
EPS (Diluted)	$-0.49+10.9%	$-0.55-22.2%	$-0.45-209.8%	$0.41+202.5%	$-0.40+33.3%	$-0.60+63.2%	$-1.63+46.6%	$-3.05

VVOS Balance Sheet

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Total Assets	$15.3M+42.4%	$10.7M-21.8%	$13.7M-59.3%	$33.7M+33.0%	$25.3M+235.4%	$7.6M
Current Assets	$7.5M+203.7%	$2.5M-54.6%	$5.4M-80.1%	$27.3M+34.0%	$20.4M+927.8%	$2.0M
Cash & Equivalents	$6.3M+281.0%	$1.6M-53.3%	$3.5M-85.4%	$24.0M+32.0%	$18.2M+3779.0%	$469K
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$430K+112.9%	$202K-55.8%	$457K-62.0%	$1.2M-15.9%	$1.4M+64.2%	$871K
Goodwill	$2.8M0.0%	$2.8M0.0%	$2.8M0.0%	$2.8M+6.4%	$2.7M0.0%	$2.7M
Total Liabilities	$7.3M-29.0%	$10.3M+15.7%	$8.9M+9.4%	$8.2M-3.1%	$8.4M-8.4%	$9.2M
Current Liabilities	$5.0M-31.7%	$7.3M+7.0%	$6.8M-9.3%	$7.5M-4.2%	$7.8M-13.8%	$9.1M
Long-Term Debt	$1.2M0.0%	$1.2M	N/A	$1.3M+199.1%	$423K-88.6%	$3.7M
Total Equity	$8.0M+1835.3%	$411K-91.4%	$4.8M-81.2%	$25.5M+51.0%	$16.9M+674.8%	-$2.9M
Retained Earnings	-$104.2M-12.0%	-$93.1M-17.1%	-$79.5M-42.9%	-$55.6M-57.4%	-$35.3M-51.8%	-$23.3M

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q3'24	Q2'24	Q1'24	Q4'23
Total Assets	$25.6M-1.5%	$26.0M+130.7%	$11.3M-26.2%	$15.3M-0.4%	$15.3M-3.1%	$15.8M+34.2%	$11.8M+10.0%	$10.7M
Current Assets	$5.8M-14.0%	$6.7M+86.6%	$3.6M-51.7%	$7.5M+1.0%	$7.4M-5.8%	$7.9M+117.4%	$3.6M+46.7%	$2.5M
Cash & Equivalents	$3.1M-29.9%	$4.4M+88.0%	$2.3M-62.6%	$6.3M-0.8%	$6.3M-8.6%	$6.9M+164.4%	$2.6M+58.9%	$1.6M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$2.1M+30.7%	$1.6M+127.4%	$718K+67.0%	$430K-5.3%	$454K+14.9%	$395K-24.8%	$525K+159.9%	$202K
Goodwill	$8.4M0.0%	$8.4M+197.2%	$2.8M0.0%	$2.8M0.0%	$2.8M0.0%	$2.8M0.0%	$2.8M0.0%	$2.8M
Total Liabilities	$23.1M+7.7%	$21.4M+212.0%	$6.9M-6.2%	$7.3M-4.6%	$7.7M-19.1%	$9.5M-15.4%	$11.2M+8.8%	$10.3M
Current Liabilities	$7.4M+15.7%	$6.4M+36.7%	$4.7M-5.6%	$5.0M-2.9%	$5.1M-22.8%	$6.6M-17.7%	$8.1M+10.7%	$7.3M
Long-Term Debt	$8.4M+8.0%	$7.8M	N/A	$1.2M0.0%	$1.2M0.0%	$1.2M	N/A	$1.2M
Total Equity	$2.5M-44.8%	$4.6M+4.0%	$4.4M-44.6%	$8.0M+3.8%	$7.7M+20.8%	$6.3M+990.5%	$582K+41.6%	$411K
Retained Earnings	-$118.5M-4.8%	-$113.1M-4.6%	-$108.1M-3.7%	-$104.2M-2.8%	-$101.4M-2.6%	-$98.7M-2.0%	-$96.8M-4.0%	-$93.1M

VVOS Cash Flow Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Operating Cash Flow	-$12.7M-6.2%	-$11.9M+39.0%	-$19.6M-24.5%	-$15.7M-177.0%	-$5.7M-6.4%	-$5.3M
Capital Expenditures	$568K-29.3%	$803K-13.1%	$924K-61.4%	$2.4M+1896.7%	$120K-31.7%	$176K
Free Cash Flow	-$13.3M-4.0%	-$12.7M+37.8%	-$20.5M-13.1%	-$18.1M-212.6%	-$5.8M-5.1%	-$5.5M
Investing Cash Flow	-$568K+33.4%	-$853K+7.7%	-$924K+64.6%	-$2.6M-2073.3%	-$120K-239.2%	$86K
Financing Cash Flow	$17.9M+63.7%	$10.9M	N/A	$24.2M+2.7%	$23.5M+426.7%	$4.5M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q3'24	Q2'24	Q1'24	Q4'23
Operating Cash Flow	-$4.2M-19.1%	-$3.5M+8.0%	-$3.8M-29.1%	-$2.9M+29.8%	-$4.2M-37.4%	-$3.0M-21.1%	-$2.5M+8.4%	-$2.7M
Capital Expenditures	-$83K-110.8%	$771K+532.0%	$122K-26.1%	$165K-14.1%	$192K+220.0%	$60K-60.3%	$151K-8.5%	$165K
Free Cash Flow	-$4.2M+0.5%	-$4.3M-8.9%	-$3.9M-26.2%	-$3.1M+29.1%	-$4.4M-40.9%	-$3.1M-16.5%	-$2.7M+8.4%	-$2.9M
Investing Cash Flow	$83K+101.4%	-$5.9M-4741.0%	-$122K+26.1%	-$165K+14.1%	-$192K-220.0%	-$60K+60.3%	-$151K+8.5%	-$165K
Financing Cash Flow	$2.8M	N/A	N/A	$3.1M-19.4%	$3.8M-48.8%	$7.4M+103.6%	$3.6M+1.9%	$3.6M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

VVOS Financial Ratios

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Gross Margin	60.0%+0.1pp	59.9%-2.6pp	62.5%-12.1pp	74.7%-5.0pp	79.7%+3.7pp	76.0%
Operating Margin	-74.3%+51.0pp	-125.3%+30.9pp	-156.2%-35.5pp	-120.7%-28.6pp	-92.2%+0.7pp	-92.8%
Net Margin	-74.1%+24.3pp	-98.4%+50.4pp	-148.8%-28.7pp	-120.2%-27.9pp	-92.3%+2.1pp	-94.4%
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-72.9%+53.7pp	-126.6%+47.2pp	-173.8%-113.6pp	-60.2%-12.6pp	-47.6%+94.8pp	-142.4%
Current Ratio	1.50+1.2	0.34-0.5	0.80-2.8	3.64+1.0	2.60+2.4	0.22
Debt-to-Equity	0.15-2.8	2.92+1.1	1.86+1.8	0.05+0.0	0.03+1.3	-1.26
FCF Margin	-88.2%+4.2pp	-92.4%+35.6pp	-128.0%-20.6pp	-107.4%-63.0pp	-44.4%+4.0pp	-48.4%

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q3'24	Q2'24	Q1'24	Q4'23
Gross Margin	58.0%+2.8pp	55.2%+5.2pp	50.0%-6.7pp	56.7%-3.8pp	60.5%-4.9pp	65.4%+8.7pp	56.6%-7.7pp	64.3%
Operating Margin	-69.8%+57.6pp	-127.4%+2.5pp	-129.9%-54.1pp	-75.8%-7.3pp	-68.5%-20.8pp	-47.8%+62.9pp	-110.7%+16.6pp	-127.3%
Net Margin	-79.6%+51.6pp	-131.2%-3.1pp	-128.1%-51.7pp	-76.4%-8.7pp	-67.8%-20.2pp	-47.6%+62.5pp	-110.1%+21.1pp	-131.1%
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-21.1%-1.8pp	-19.3%+15.0pp	-34.3%-15.8pp	-18.5%-1.4pp	-17.1%-4.9pp	-12.2%+19.7pp	-31.9%+7.8pp	-39.7%
Current Ratio	0.78-0.3	1.05+0.3	0.77-0.7	1.50+0.1	1.44+0.3	1.18+0.7	0.45+0.1	0.34
Debt-to-Equity	3.31+1.6	1.69+0.1	1.56+1.4	0.150.0	0.16-0.0	0.19-19.1	19.28+16.4	2.92
FCF Margin	-62.6%+49.1pp	-111.7%+18.3pp	-129.9%-45.9pp	-84.0%+29.5pp	-113.5%-36.8pp	-76.7%+1.3pp	-78.0%+11.7pp	-89.7%

Similar Companies

$21.0M

$26.2M

$54.6M

$28.1M

$23.9M

Frequently Asked Questions

What is Vivos Therapeutics Inc's annual revenue?

Vivos Therapeutics Inc (VVOS) reported $15.0M in total revenue for fiscal year 2024. This represents a 8.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Vivos Therapeutics Inc's revenue growing?

Vivos Therapeutics Inc (VVOS) revenue grew by 8.9% year-over-year, from $13.8M to $15.0M in fiscal year 2024.

Is Vivos Therapeutics Inc profitable?

No, Vivos Therapeutics Inc (VVOS) reported a net income of -$11.1M in fiscal year 2024, with a net profit margin of -74.1%.

What is Vivos Therapeutics Inc's earnings per share (EPS)?

Vivos Therapeutics Inc (VVOS) reported diluted earnings per share of $-2.22 for fiscal year 2024. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

What is Vivos Therapeutics Inc's EBITDA?

Vivos Therapeutics Inc (VVOS) had EBITDA of -$10.6M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Vivos Therapeutics Inc have?

As of fiscal year 2024, Vivos Therapeutics Inc (VVOS) had $6.3M in cash and equivalents against $1.2M in long-term debt.

What is Vivos Therapeutics Inc's gross margin?

Vivos Therapeutics Inc (VVOS) had a gross margin of 60.0% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.

What is Vivos Therapeutics Inc's operating margin?

Vivos Therapeutics Inc (VVOS) had an operating margin of -74.3% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.

What is Vivos Therapeutics Inc's net profit margin?

Vivos Therapeutics Inc (VVOS) had a net profit margin of -74.1% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.

What is Vivos Therapeutics Inc's free cash flow?

Vivos Therapeutics Inc (VVOS) generated -$13.3M in free cash flow during fiscal year 2024. This represents a -4.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Vivos Therapeutics Inc's operating cash flow?

Vivos Therapeutics Inc (VVOS) generated -$12.7M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Vivos Therapeutics Inc's total assets?

Vivos Therapeutics Inc (VVOS) had $15.3M in total assets as of fiscal year 2024, including both current and long-term assets.

What are Vivos Therapeutics Inc's capital expenditures?

Vivos Therapeutics Inc (VVOS) invested $568K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.

How much does Vivos Therapeutics Inc spend on research and development?

Vivos Therapeutics Inc (VVOS) invested $100K in research and development during fiscal year 2024.

How many shares does Vivos Therapeutics Inc have outstanding?

Vivos Therapeutics Inc (VVOS) had 6M shares outstanding as of fiscal year 2024.

What is Vivos Therapeutics Inc's current ratio?

Vivos Therapeutics Inc (VVOS) had a current ratio of 1.50 as of fiscal year 2024, which is generally considered healthy.

What is Vivos Therapeutics Inc's debt-to-equity ratio?

Vivos Therapeutics Inc (VVOS) had a debt-to-equity ratio of 0.15 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Vivos Therapeutics Inc's return on assets (ROA)?

Vivos Therapeutics Inc (VVOS) had a return on assets of -72.9% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is Vivos Therapeutics Inc's cash runway?

Based on fiscal year 2024 data, Vivos Therapeutics Inc (VVOS) had $6.3M in cash against an annual operating cash burn of $12.7M. This gives an estimated cash runway of approximately 6 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Vivos Therapeutics Inc's Piotroski F-Score?

Vivos Therapeutics Inc (VVOS) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Vivos Therapeutics Inc's earnings high quality?

Vivos Therapeutics Inc (VVOS) has an earnings quality ratio of 1.14x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Vivos Therapeutics Inc?

Vivos Therapeutics Inc (VVOS) scores 39 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.